A Phase 2/3 interventional study of DA-001 and Placebo in Telogen Effluvium, Female Pattern Hair Loss and Female Pattern Hair Loss, Androgenic Alopecia, sponsored by Applied Biology, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Applied Biology, Inc. · Phase 2/3, Interventional, and Treatment
The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth
DA-001 is a topical alpha 1 agonist combined with a TAAR receptor agonist. DA-001 was studied in a population of women that suffer from excessive hair shedding. DA-001 demonstrated significant reduction in hair shedding.
This study aims to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth.
511 studies on the registry are indexed under Alopecia; 128 are open to participants now.
This study's planned enrollment of 1,120 is above the median of 50 across 430 interventional studies indexed under Alopecia.
Browse Alopecia studies →Applied Biology, Inc. is the lead sponsor of 25 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phenylephrine 2.5% Topical + TAAR agonist
Drug: DA-001
Placebo
Other: Placebo
Phenylephrine 2.5% Topical (per application volume - males 5mL and females 20mL)
Drug: Phenylephrine
DA-001 Topical (Phenylephrine 2.5% Topical + TAAR agonist tyramine) + DA-005 Oral (HIF-1α supplement)
Other: DA-001 Topical + DA-005 Oral (HIF-1α supplement)
Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)
Other: DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)
Phenylephrine Topical 0.25% + Intact Pro Topical
Drug: Phenylephrine Topical 0.25% + Intact Pro Topical
Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement)
Other: Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement)
Phenylephrine 2.5% Topical + TAAR Agonist (GRAS) Topical Solution
Placebo Topical Solution
Phenylephrine 2.5% Topical
DA-001 Topical (Phenylephrine 2.5% Topical + TAAR agonist tyramine) + DA-005 Oral (HIF-1α supplement)
Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)
Phenylephrine 0.25% + Intact Pro (50% stronger)
Phenylephrine 0.25% + Intact Pro (50% stronger) + DA-005 Oral (HIF-1α supplement)
Mean Change in Hair Shedding
Number of hairs shedding during brushing at target area
Time frame: Minutes [0,5]
Mean Change in Hair Shedding
Number of hairs shedding during brushing at target area
Time frame: Week [0, 4, 12, 24]
Mean Change in Target Area Hair Count (TAHC)
Number of hairs in a 1-cm² target scalp area
Time frame: Week [0, 4, 12, 24]
No study locations are listed for this record.
Plan to share: No
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phenylephrine